LITTLE FALLS, N.J.,
Dec. 5, 2013 /PRNewswire/
-- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 17%
increase in net income to a record $11,185,000, or $0.27 per diluted share, on a 19% increase in
sales to a record $118,272,000 for
the first quarter ended October 31,
2013. This compares with net income of $9,576,000, or $0.23 per diluted share, on sales of $99,681,000 for the first quarter ended
October 31, 2012.
Andrew Krakauer, Cantel's
President and CEO stated, "We are pleased to have delivered record
sales and earnings this quarter. We achieved good financial
performance in all three major business segments – Endoscopy, Water
Purification and Filtration, and Healthcare Disposables. All three
business units have greatly benefitted from further investments in
new product development, sales and marketing programs, and the
integration of recent acquisitions. Most importantly, for the
second consecutive quarter we had strong organic sales growth of
10%. Further, our total sales growth of 19% demonstrates the
success of our acquisition program."
Krakauer added, "Our Medivators Endoscopy business achieved
robust organic sales growth of 19% in the quarter. All product
categories were strong, including equipment, disinfectant
chemicals, procedural products, as well as service and spare parts.
Our Mar Cor Water Purification and Filtration segment continued its
excellent performance as it has for the past two years with sales
growth of 20% this quarter. Higher sales in this segment were led
by increased shipments of central and portable water purification
equipment. Sales in our Crosstex Healthcare Disposables business
grew by 32%, mostly driven by the successful integration of the SPS
Medical sterility assurance acquisition completed in November 2012. These substantial revenue
increases drove the significantly improved operating earnings. Our
strong results validate the effectiveness of our increasing
investments in sales and marketing and new product development,
which will support continued growth in all our major segments.
Further, we are also taking an aggressive approach in building our
international sales, marketing and operations teams to grow this
part of our business over the medium-term. Such investments will
accelerate over the next several quarters. Cantel will continue to
be dedicated to the growing global infection prevention and control
marketplace through both organic growth strategies and our
continued commitment to an active acquisition program."
The Company also reported that its balance sheet at October 31, 2013 included current assets of
$151,293,000, including cash of
$28,453,000, a current ratio of
2.5:1, gross debt of $82,000,000 and
stockholders' equity of $330,434,000.
Krakauer stated, "We continue to maintain a strong balance sheet
and generate substantial cash flow and EBITDAS. When compared with
the same quarter last year, our EBITDAS grew by 15% to $24,148,000. We were able to reduce our net debt
position by over $7 million to
$53,547,000, during the quarter."
Cantel Medical is a leading global company dedicated to
delivering innovative infection prevention and control products and
services for patients, caregivers, and other healthcare providers
which improve outcomes, enhance safety and help save lives.
Our products include specialized medical device reprocessing
systems for endoscopy and renal dialysis, advanced water
purification equipment, sterilants, disinfectants and cleaners,
sterility assurance monitoring products for hospitals and dental
clinics, disposable infection control products primarily for dental
and GI endoscopy markets, dialysate concentrates, hollow fiber
membrane filtration and separation products, and specialty
packaging for infectious and biological specimens. Additionally, we
provide technical service for our products.
The Company will hold a conference call to discuss the results
for the first quarter ended October 31,
2013 on Thursday, December 5,
2013 at 11:00 AM Eastern time.
To participate in the conference call, dial (877) 407-8033
approximately 5 to 10 minutes before the beginning of the call. If
you are unable to participate, a digital replay of the call will be
available from Thursday, December 5,
2013 at 2:00 PM through
midnight on February 5, 2014 by
dialing (877) 660-6853 and using conference ID # 13573107.
The call will be simultaneously broadcast live over the Internet
on vcall.com at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171967. A
replay of the webcast will be available on Vcall for 90 days and
via the investor relations page of the Cantel web site.
For further information, visit the Cantel website at
www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
CANTEL MEDICAL
CORP.
|
CONDENSED
CONSOLIDATED STATEMENTS OF INCOME
|
(In thousands, except
per share data)
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
|
October
31,
|
|
|
|
2013
|
|
2012
|
|
|
|
|
|
|
|
Net sales
|
|
$
118,272
|
|
$
99,681
|
|
|
|
|
|
|
|
Cost of
sales
|
|
66,773
|
|
55,954
|
|
|
|
|
|
|
|
Gross
profit
|
|
51,499
|
|
43,727
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
Selling
|
|
15,764
|
|
13,413
|
|
General and
administrative
|
|
15,164
|
|
12,048
|
|
Research and
development
|
|
2,259
|
|
2,294
|
|
Total operating
expenses
|
|
33,187
|
|
27,755
|
|
|
|
|
|
|
|
Income before
interest and income taxes
|
|
18,312
|
|
15,972
|
|
|
|
|
|
|
|
Interest
expense
|
|
657
|
|
646
|
|
Interest
income
|
|
(13)
|
|
(13)
|
|
|
|
|
|
|
|
Income before income
taxes
|
|
17,668
|
|
15,339
|
|
|
|
|
|
|
|
Income
taxes
|
|
6,483
|
|
5,763
|
|
|
|
|
|
|
|
Net
income
|
|
$
11,185
|
|
$
9,576
|
|
|
|
|
|
|
|
Earnings per common
share - diluted
|
|
$
0.27
|
|
$
0.23
|
|
|
|
|
|
|
|
Dividends per common
share
|
|
$
0.05
|
|
$
0.04
|
|
|
|
|
|
|
|
Weighted average
shares - diluted
|
|
41,373
|
|
41,042
|
|
|
|
|
|
|
CANTEL MEDICAL
CORP.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(In
thousands)
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
October
31,
|
|
July 31,
|
|
|
2013
|
|
2013
|
Assets
|
|
|
|
|
Current assets
|
|
$
151,293
|
|
$
150,660
|
Property and equipment,
net
|
|
46,565
|
|
46,465
|
Intangible assets,
net
|
|
73,512
|
|
75,929
|
Goodwill
|
|
211,429
|
|
211,618
|
Other assets
|
|
3,019
|
|
2,999
|
|
|
$
485,818
|
|
$
487,671
|
|
|
|
|
|
Liabilities and stockholders' equity
|
|
|
|
Current portion of long-term
debt
|
|
$
10,000
|
|
$
10,000
|
Other current
liabilities
|
|
49,988
|
|
49,151
|
Long-term debt
|
|
72,000
|
|
85,000
|
Other long-term
liabilities
|
|
23,396
|
|
22,388
|
Stockholders'
equity
|
|
330,434
|
|
321,132
|
|
|
$
485,818
|
|
$
487,671
|
|
|
|
|
|
SUPPLEMENTARY
INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Earnings Before Interest, Taxes, Depreciation, Amortization and
Stock-Based
|
Compensation
Expense ("EBITDAS")
|
|
|
|
|
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The reconciliation of
EBITDAS with net income for the three months ended October 31, 2013
and 2012,
|
respectively, is as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
|
|
|
|
October
31,
|
|
|
|
|
|
|
2013
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
11,185
|
|
$
9,576
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
taxes
|
|
6,483
|
|
5,763
|
|
|
|
|
Interest
expense
|
|
657
|
|
646
|
|
|
|
|
Interest
income
|
|
(13)
|
|
(13)
|
|
|
|
|
Depreciation
|
|
1,937
|
|
1,760
|
|
|
|
|
Amortization
|
|
2,626
|
|
2,267
|
|
|
|
|
Loss on disposal of
fixed assets
|
|
125
|
|
41
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
|
23,000
|
|
20,040
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation expense
|
|
1,148
|
|
958
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDAS
|
|
$
24,148
|
|
$
20,998
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDAS is a measure
of the Company's performance that is not required by, or presented
in accordance with,
Generally Accepted
Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial
measure defined by the
Company as income
before interest, taxes, depreciation, amortization and stock-based
compensation expense.
The Company believes
EBITDAS is an important valuation measurement for management and
investors given
the increasing effect
that non-cash charges, such as stock-based compensation,
amortization related to acquisitions and depreciation of capital equipment, has on the
Company's net income. In particular, acquisitions have
historically resulted in
significant increases in amortization of intangible assets that
reduced the Company's net income. Additionally, the Company regards EBITDAS as a useful
measure of operating performance and cash flow before
the effect of interest expense and
complements operating income, net income and other GAAP
financial
performance measures.
Generally, a non-GAAP financial measure is a numerical measure of a
Company's
performance,
financial position or cash flow that either excludes or includes
amounts that are not normally excluded or included in the most directly comparable measure
calculated and presented in accordance with GAAP.
This measure,
however, should be considered in addition to, and not as a
substitute or superior to, net income, cash flows, or other measures of financial
performance prepared in accordance with GAAP.
|
SOURCE Cantel Medical Corp.